James Enlou Tcheng

Journal article Circulation · February 16, 2010 Featured Publication BACKGROUND: Eptifibatide reduces major adverse cardiac events in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI). Intracoronary bolus administration of eptifibatide may result in higher levels of platelet glycopro ... Full text Link to item Cite

Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion.

Journal article JACC Cardiovasc Interv · December 2009 Featured Publication Full text Link to item Cite

Prasugrel: Clinical development and therapeutic application.

Journal article Adv Ther · November 2009 Featured Publication Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention. Despite the proven benefits, clear limitations of clopidogrel exist. Prasu ... Full text Link to item Cite

Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.

Journal article Circ Cardiovasc Interv · February 2009 Featured Publication BACKGROUND: Only limited data describe relationships between stent parameters (length and diameter), adverse events after percutaneous coronary intervention, and effects of platelet glycoprotein IIb/IIIa blockade by stent parameters. METHODS AND RESULTS: I ... Full text Link to item Cite

Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions.

Journal article Am Heart J · May 2008 Featured Publication In 2006, the American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions published the 2005 update of the evidence-based guidelines for the treatment of patients undergoing percutaneous coronary intervention (PC ... Full text Link to item Cite

Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.

Journal article Am J Cardiol · November 1, 2007 Featured Publication Adjunctive pharmacotherapy for stabilizing patients with acute coronary syndrome/non-ST-segment elevation myocardial infarction (ACS/NSTEMI) and for subsequent percutaneous coronary intervention (PCI) includes a combination of anticoagulant and antiplatele ... Full text Link to item Cite

Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.

Journal article Catheter Cardiovasc Interv · July 1, 2007 Featured Publication OBJECTIVES: This analysis sought to investigate the complementary effect of thienopyridine pretreatment and platelet glycoprotein (GP) IIb/IIIa integrin blockade in coronary stent intervention. BACKGROUND: Definitive evidence supporting combined antiplatel ... Full text Link to item Cite

After fibrinolysis: is cardiac catheterization the answer?

Journal article J Am Coll Cardiol · October 3, 2006 Featured Publication Full text Link to item Cite

Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.

Journal article J Interv Cardiol · October 2006 Featured Publication Substantial controversy exists regarding the optimal pharmacologic cocktail for percutaneous coronary intervention (PCI). The most common approach typically includes aspirin, clopidogrel, unfractionated heparin (or enoxaparin), and (variably) a glycoprotei ... Full text Link to item Cite

Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.

Journal article J Am Coll Cardiol · February 21, 2006 Featured Publication OBJECTIVES: In order to determine a differential benefit from treatment, we compared the long-term outcome of high-risk versus low-risk patients and evaluated survival free from death or myocardial infarction at one year. BACKGROUND: Newer anticoagulant st ... Full text Link to item Cite

Quantitative and qualitative comparison of text-based and graphical user interfaces for Computerized Provider Order Entry.

Journal article AMIA Annu Symp Proc · 2006 Featured Publication Limited prospective data exist that define advantages and disadvantages of text-based versus graphical user interfaces in Computerized Provider Order Entry (CPOE). We created a single set of admission orders in both formats and, using a randomized crossove ... Link to item Cite